During induction of anaesthesia with etomidate, myoclonic muscle movements are frequent. In this study, pretreatment with a small dosage of etomidate or midazolam was compared with placebo for the prevention of myoclonic muscle movements. Sixty patients, premedicated with oral midazolam, were pretreated in a randomized double-blinded fashion with etomidate 0.05 mg/kg IV, midazolam 0.015 mg/kg IV or normal saline IV (placebo) in three groups of 20 patients each. The pretreatment was followed after 90 seconds by etomidate 0.3 mg/kg IV. One minute after onset of hypnosis, induction of anaesthesia was completed with sufentanil and rocuronium. From the time of pretreatment to completion of anaesthesia, patients were observed for myoclonic muscle movements by a single physician, blinded to group allocation. Myoclonic movements were graded on a scale of 0 to 3. The incidence of myoclonic movements was significantly lower in patients pretreated with midazolam (4 of 20) compared with placebo (18/20) (P<0.01). Midazolam 0.015 mg/kg IV, administered 90 seconds before induction of anaesthesia with etomidate, is effective in reducing etomidate-induced myoclonic muscle movements.
The imidazole derivate etomidate is a useful induction agent with minimal respiratory side-effects and histamine release, and a very stable haemodynamic profile. Therefore etomidate is frequently used for haemodynamically unstable patients 1, 2 . Whereas one side-effect of etomidate, pain on injection, was abolished by formulation in a new fat emulsion, myoclonic movements remain a common problem during induction. Up to 80% of unpremedicated patients develop myoclonic movements after receiving etomidate 1 . This incidence can be reduced by pretreatment with fentanyl [3] [4] [5] [6] . A recent study has suggested that a new approach to suppression of myoclonic movements during induction with etomidate could be pretreatment with a small dose of etomidate prior to the hypnotic dose 7 . Although benzodiazepine premedication appears, from the literature, to be relatively ineffective at reducing these myoclonic muscle movements, the effectiveness of co-induction with midazolam is unknown.
Thus, the aim of this study was to compare the effect of pretreatment with etomidate or midazolam versus placebo on the incidence and severity of myoclonic movements during induction of anaesthesia with etomidate.
MATERIALS AND METHODS
The study was approved by the Ethics Committee of the Friedrich-Schiller-University, Jena. Before participating, patients gave their written informed consent. Study enrolment took place during an eleven-month period in 2000 at a university hospital. Sixty adult patients (ASA physical status 1-3) without neurologic disease were included. They were scheduled for elective gynaecological, ophthalmologic or urological surgery. Patients were premedicated with 25 to 50 mg clorazepate dipotassium orally the evening before surgery. Midazolam 7.5 mg was given orally one hour before induction of anaesthesia. After arrival at the operating room an intravenous line was established and isotonic saline solution, stored at operating room temperature, was infused at 15 to 20 ml/kg/h. The ambient temperature in the operating room was maintained at 20 to 22°C. Heart rate, noninvasive arterial blood pressure, and oxygen saturation were recorded every minute during the study period (AS 3, Datex, Helsinki, Finland). Patients were allocated in a randomized and doubleblinded fashion to one of three pretreatment groups (n=20 per group): etomidate 0.05 mg/kg IV, midazolam 0.015 mg/kg IV or normal saline IV. The solutions were prepared in a black syringe, outside the operating room, by a person not involved in the induction of anaesthesia. Randomization was achieved using a computer-generated list. The anaesthetist performing the induction and the patient were not aware of the pretreatment drug. Ninety seconds after administration of the study solution, anaesthesia was induced with etomidate 0.3 mg/kg IV. At 60 seconds after administration of the induction dose of etomidate, sufentanil 0.2 µg/kg IV and rocuronium 0.6 mg/kg IV were given as a bolus injection to facilitate tracheal intubation. After intubation, anaesthesia was maintained with isoflurane or sevoflurane (MAC 1.0±0.3) in a mixture of nitrous oxide in oxygen (2:1). No other drugs were used between premedication and the end of induction. Patients were observed continuously by a single physician between the time of pretreatment and completion of induction of anaesthesia with sufentanil and rocuronium, looking for myoclonic movements. The observer was blinded to group allocation. It was decided to investigate this period of 60 seconds after the administration of the hypnotic dosage of etomidate, because this simulated the time to onset of rapid onset neuromuscular blocking agents that are usually given immediately after the hypnotic agent during rapid sequence induction. Myoclonic movements were defined as any abnormal muscle movements. The intensity of myoclonic movement was graded as 0= no myoclonic movement, 1=mild myoclonic movement, 2=modest myoclonic movement, and 3= severe myoclonic movement. We expected the rate of myoclonic movements in the placebo group to be 0.7. Using an α=0.05 and β=0.2 power analysis showed that for a reduction rate of 0.4 for a treatment versus placebo, a minimum of 19 patients would have to be included in each of the three groups. Statistical analyses were performed with the Chi-squared test and the analyses of variance. Tests were performed with the computing program "Statistical Packet for the Social Sciences" SPSS (9th version, SPSS Inc., Chicago, IL, U.S.A.). All group data are expressed as mean (±SD). A P value <0.05 identified statistically significant differences.
RESULTS
There were no significant differences between the patients in the three groups (n=20 per group) with regard to age, gender, ASA physical status and height. Body weight was greater among patients in the placebo group (Table 1) .
Between pretreatment and induction of anaesthesia with etomidate all patients in all pretreatment groups remained conscious.
Pretreatment with midazolam significantly reduced myoclonic movements after injection of etomidate (P<0.01). Only 4/20 patients pretreated with midazolam, but 18/20 of the patients treated with placebo, and 15/20 of the patients pretreated with a small dose of etomidate, developed myoclonic movements during the 60 second period following induction with etomidate ( Table 2 ).
The intensity of myoclonic movements is also shown in Table 2 . The three groups were comparable with regard to heart rate and blood pressure values during the study period.
DISCUSSION
We found that pretreatment with midazolam 0.015 mg/kg IV significantly reduced the incidence of myoclonic movements during induction of anaesthesia with etomidate.
In other studies, pretreatment with other benzodiazepines such as diazepam (0.0625 to 0.125 mg/kg IV) or flunitrazepam (0.01 mg/kg IV) failed to reduce myoclonic movements 3, 5 with IV midazolam in our study may be because of the faster onset of this drug. Pretreatment with etomidate 0.05 mg/kg IV did not reduce myoclonic movements in our study. This result is contrary to the findings of Doenicke and coworkers 7 who showed that pretreatment with a small dose of etomidate reduced myoclonic movements in an experimental setting involving a small group of unpremedicated volunteers (n=8). Myoclonic movements were reduced from 75% during induction of anaesthesia without pretreatment to 25% with pretreatment. A larger trial (n=20 in each group) without a control group in premedicated patients, described by the same author in the same publication, also found etomidate to be effective in reducing myoclonic movements at any of three different dosages (etomidate 0.03, 0.05 or 0.075 mg/kg IV).
Because pretreatment with fentanyl or alfentanil is an effective way of reducing myoclonic movements, these drugs may be useful during longer procedures [3] [4] [5] [6] 8 . However, in some cases pretreatment with longer acting drugs like fentanyl may have unwelcome side-effects: for short procedures, such as elective cardioversion, rapid disappearance of residual effects is desirable 9, 10 .
For ethical reasons all patients enrolled in our study were premedicated with 25 to 50 mg clorazepate dipotassium orally the evening before surgery and midazolam 7.5 mg orally one hour before induction of anaesthesia. In spite of this premedication myoclonic muscle movements were common during the study period. The effect of oral premedication with benzodiazepines on myoclonic activity seems to be relatively indistinct: successful prevention of involuntary muscle movements by premedication with diazepam (10 to 20 mg orally one hour before induction of anaesthesia) has been only reported by Holdcroft and co-workers 11 , whereas Famewo and Odugbesan failed to show a benefit 12 . Whether a dose of midazolam of 0.015 mg/kg IV would be sufficient to suppress myoclonic muscle movement in unpremedicated patients is a field for further investigation.
In conclusion, pretreatment with midazolam (0.015 mg/kg IV) modifies the induction of anaesthesia with etomidate by reducing the incidence of myoclonic movements and preserves the advantages of etomidate: cardiovascular stability and short duration of action.
